We read with great interest the study by Engvall and colleagues [1] in a recent issue of Arthritis Research & Th erapy. Th e study showed that anti-tumor necrosis factor-alpha (anti-TNF-α) infl iximab therapy is associated with an increase of body fat mass in early rheumatoid arthritis (RA) independently of changes in disease activity and levels of leptin and adiponectin.
P-selectin concentrations (r = −0.513; P = 0.002) [3] . How ever, ghrelin concentrations were not related to the DAS28 (disease activity score using 28 joint counts), the mean erythrocyte sedimentation rate (ESR), and Creactive protein (CRP) from disease diagnosis or the ESR, platelet count, CRP, or cumulative prednisone dose at the time of the study [3] . Moreover, we observed a signifi cant correlation between leptin levels and body mass index [4] .
Apart from stimulating growth hormone production, ghrelin regulates energy homeostasis through increasing food intake and decreasing fat utilization, leading to increased adiposity through growth hormone-independent mechanisms [5] . Ghrelin is further associated with metabolic syndrome features, and ghrelin administration has benefi cial eff ects not only on cachexia in patients with heart failure and chronic obstructive pulmonary disease but also on insulin sensitivity in overweight patients and endothelial dysfunction in patients with metabolic syndrome [6] . Additionally, ghrelin has potent anti-infl ammatory eff ects, including the inhibition of proinfl ammatory cytokine production by T lymphocytes and monocytes within the immune system and human endothelial cells [7] . Besides noting the rapid decrease of P-selectin, a biomarker of endothelial dysfunction [8] , we observed a rapid and signifi cant improvement of endothelial function following infl iximab administration in these patients [9] .
According to our observations, anti-TNF-α therapy increases serum levels of ghrelin. Since ghrelin has antiinfl ammatory eff ects, increased levels presumably would be additive to the effi cacious actions of infl iximab [3] .
Metabolic syndrome features are independently associated with atherosclerosis in RA [10] . However, in our series of patients with severe RA, in contrast to what was reported in non-RA subjects, metabolic syndrome features were not related to ghrelin concentrations [3] . It is possible that improvement of ghrelin metabolism through inhibition of cytokine production attenuates the cachexia in patients with RA. Additionally, in our series, we observed a signifi cant increase of body mass index when values obtained before the onset of infl iximab therapy were compared with those observed after 2 years of infl iximab therapy (unpublished observations). Considering all of these observations, we feel that, in patients with severe RA, the TNF-α blockade may improve the impaired production of ghrelin, a hormone that is implicated in RA-associated cachexia. Th is eff ect may lead to an increase of body mass index in RA patients undergoing TNF-α antagonist therapy.
Abbreviations CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquartile range; RA, rheumatoid arthritis; TNF-α, tumor necrosis factor-alpha.
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